(FBIOP) Investment Analysis and Advice

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Fortress Biotech to Participate in October 2024 Investor Conferences
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.